• Technology
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

Applications of proteomics in neuroscience: Diving into the role of tau in health and disease with interaction proteomics

August 3, 2023
Tyler Ford
LinkedInTwitter

Image displaying some of the techniques used in interactions proteomics. The top of the image reads, "Diving into the role of tau in health and disease with interaction proteomics." On the left there is a depiction of APEX followed by mass spectrometry with text reading "APEX-tagged tau labels proteins near the APEX tag. Isolate and identify labeled proteins with mass spectrometry." The right side of the image depicts affinity purification followed by mass spectrometry with text that reads, "Purify tau and any proteins bound to it. Extract and identify the bound proteins with mass spectrometry."

 

The molecular mechanisms underlying Alzheimer’s disease are poorly understood but are associated with the aggregation of beta amyloid protein outside neurons and tau protein inside neurons. How the aggregation of these proteins relates to the underlying mechanisms of the disease is not well understood. Aggregation could be a symptom or a cause of the disease. To better understand the roles of tau and beta amyloid in both health and disease, researche­rs have begun to leverage the incredible power of proteomics.

 

With specific reference to the tau protein, Tracy, et al recently used interaction proteomics to profile the proteins that wildtype and pathogenic varieties of tau interact with. Their work points to roles for tau in synaptic vesicle trafficking and cellular energetics that may be negatively impacted in Alzheimer’s disease. These findings may enable the development of biomarkers and treatments focused on these pathways.

 

 

This post is a snippet from our “Proteomics and neuroscience eBook.” Download the full eBook by clicking the button below.

Download the eBook

 

Interaction proteomics reveals associations between tau and synaptic proteins as well as with mitochondrial proteins

With interaction proteomics, researchers label and/or isolate proteins that interact with a protein of interest and profile these interaction partners using techniques like mass spectrometry. This reveals associations between a protein of interest and other components of a cell’s molecular machinery. Consistent associations between a protein of interest and other proteins with particular functions indicate that the protein of interest is involved in those functions.

 

In this work, Tracy, et al differentiated human induced pluripotent stem cells (iPSCs) into neurons and performed two types of interaction proteomics with them:

 

  • APEX labeling followed by mass spectrometry
  • Affinity purification followed by mass spectrometry

 

In the APEX labeling experiments, researchers genetically tagged various forms of tau with the APEX protein in iPSC-derived neurons. Under the proper conditions, APEX will add a biotin molecule to any tyrosines on proteins near the APEX-tagged tau. Using biotin binding antibodies, researchers extracted the biotin-labeled proteins from the cells and used mass spectrometry to identify them. This revealed all the proteins that were in close enough proximity to APEX-tau to be labeled.

 

Results from the APEX experiments showed that associations between tau and other proteins change upon neuronal stimulation. For example, the researchers saw increased association with synaptic vesicle proteins upon neuronal stimulation, suggesting that interactions with these proteins may facilitate tau release at synapses and may enable tau to spread between neurons.

 

These researchers used affinity purification and mass spectrometry to reveal proteins that have longer-lived interactions with tau. Here, they used antibodies to purify tau and any other proteins that were bound to it. Then these binding partners were released and identified via mass spectrometry.

 

Results from the affinity purification experiments showed that there were differential associations between wild-type tau and mutated versions of tau known to be associated with genetic forms of dementia. Mutant tau proteins interacted less with mitochondrial proteins and cells producing mutated tau had impaired energetics compared to those producing wildtype tau. In addition, when the researchers looked at the abundance of tau-interacting proteins from mitochondria in people with Alzheimer’s, they discovered that decreases in these interacting proteins were associated with increased disease severity.

 

These results point to impaired energetics as a possible mechanism of tau-induced neuron dysfunction in Alzheimer’s. Future treatments could be designed to counteract these energetic effects.

 

Enabling more studies of protein interaction and function with next-generation proteomics

This study demonstrates the incredible power of proteomics to reveal the functions of proteins in both normal biology and disease. While studies like this are currently restricted to a small number of labs where researchers have the expertise to complete them, next-generation proteomics technologies like the Nautilus Proteome Analysis Platform aim to make such work far more accessible. We are designing our platform to enable many more studies like this and provide unforeseen insights into human health that will make it possible to exquisitely target diseases like Alzheimer’s at the molecular level.

Browse by topic

  • Nautilus in the News
  • Events
  • Research and Collaborations
  • Applications of Proteomics
  • Nautilus and our Platform
  • Proteomics
  • Life at Nautilus
  • Industry Interviews
SUBSCRIBE
Back To Blog

Nautilus Biotechnology

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

 

     

+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

We use cookies in order to continually improve your experience on our website. By clicking “Accept cookies” or clicking on any content on our site, you are consenting to our use of cookies as described in our Privacy Policy. You can opt-out if you wish. Accept Reject All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT